AM7499

Home
Ligands
AM7499

Ligand id: 9257

Name: AM7499

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	3
Hydrogen bond donors	2
Rotatable bonds	7
Topological polar surface area	75.99
Molecular weight	404.26
XLogP	3.99
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Classification
Compound class	Synthetic organic

IUPAC Name
butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-3-yl]-2-methylpropanoate

IUPAC Name

butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-3-yl]-2-methylpropanoate

Synonyms
compound 3b [PMID: 27367336]

Synonyms

compound 3b [PMID: 27367336]

Database Links
GtoPdb PubChem SID	315661332
PubChem CID	121231416
Search Google for chemical match using the InChIKey	OSVHLUXLWQLPIY-KBAYOESNSA-N
Search Google for chemicals with the same backbone	OSVHLUXLWQLPIY
Search UniChem for chemical match using the InChIKey	OSVHLUXLWQLPIY-KBAYOESNSA-N
Search UniChem for chemicals with the same backbone	OSVHLUXLWQLPIY

Comments
AM7499 is a non-selective cannabinoid receptor agonist [1]. It has been designed to be readily hydrolysed by plasma esterases (to shorten its duration of action; such compounds are being called 'controlled-deactivation cannabinoids') and to be less prone to deposition in bodily fat than existing classical cannabinoid agonists. This strategy has been adopted to produce cannabinoid agonists with improved drug-like qualities and potentially a more favourable safety profile.

Comments

AM7499 is a non-selective cannabinoid receptor agonist [1]. It has been designed to be readily hydrolysed by plasma esterases (to shorten its duration of action; such compounds are being called 'controlled-deactivation cannabinoids') and to be less prone to deposition in bodily fat than existing classical cannabinoid agonists. This strategy has been adopted to produce cannabinoid agonists with improved drug-like qualities and potentially a more favourable safety profile.